董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Shmuel Ben Zvi | 男 | Independent Director | 65 | 3.34万美元 | 未持股 | 2025-08-24 |
| Dror Bashan | 男 | Director, President and Chief Executive Officer | 58 | 146.83万美元 | 未持股 | 2025-08-24 |
| Eliot Richard Forster | -- | Chairman of the Board | -- | 未披露 | 未持股 | 2025-08-24 |
| Christian Elze | -- | Director | -- | 未披露 | 未持股 | 2025-08-24 |
| Pol F. Boudes | 男 | Independent Director | 68 | 6.15万美元 | 未持股 | 2025-08-24 |
| Amos Bar Shalev | 男 | Independent Director | 72 | 6.15万美元 | 未持股 | 2025-08-24 |
| Aharon Schwartz | 男 | Independent Director | 82 | 6.15万美元 | 未持股 | 2025-08-24 |
| Gwen A. Melincoff | 女 | Independent Director | 73 | 6.15万美元 | 未持股 | 2025-08-24 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Gilad Mamlok | 男 | Senior Vice President and Chief Financial Officer | 56 | 未披露 | 未持股 | 2025-08-24 |
| Dror Bashan | 男 | Director, President and Chief Executive Officer | 58 | 146.83万美元 | 未持股 | 2025-08-24 |
| Yaron Naos | 男 | Senior Vice President, Operations | 61 | 53.33万美元 | 未持股 | 2025-08-24 |
| Gilad Mamlok | 男 | Senior Vice President and Chief Financial Officer | 57 | 未披露 | 未持股 | 2025-08-24 |
董事简历
中英对照 | 中文 | 英文- Shmuel Ben Zvi
-
Shmuel Ben Zvi在我们的首次公开募股定价后立即成为我们的董事会成员。Ben Zvi博士目前是Bank Leumi的董事会成员和审计、风险管理、技术和战略委员会成员，以及VBL Therapeutics的董事会成员和审计委员会成员。从2004年到2014年，Ben Zvi博士担任梯瓦制药工业有限公司（Teva Pharmaceuticals Industries Ltd.）的多个管理职位，包括财务Vice President和战略Vice President。从2000年到2004年，Ben Zvi博士是以色列国防军总参谋长的财务顾问和国防部预算司司长。Ben Zvi博士拥有以色列特拉维夫大学（Tel-Aviv University）经济学博士学位，并参加了哈佛商学院高级管理课程AMP。
Shmuel Ben Zvi became a member of Sol-Gel Technologies Ltd. board of directors immediately following pricing of Sol-Gel Technologies Ltd. initial public offering. Dr. Ben Zvi is currently a board ember and member of the risk management, technology, investment and strategy committees at Bank Leumi, and a board member and member of the audit committee and compensation committee of VBL Therapeutics. From 2004 to 2014 Dr. Ben Zvi held various managerial positions at Teva Pharmaceuticals Industries Ltd., including Vice President of Finance and Vice President of Strategy. From 2000 to 2004 Dr. Ben Zvi was the financial advisor to the Chief of General Staff of the Israel Defense Forces and head of the Defense Ministry budget department. Dr. Ben Zvi holds a Ph.D. in economics from Tel-Aviv University, Israel and participated in the Harvard Business School Advanced Management Program AMP. - Shmuel Ben Zvi在我们的首次公开募股定价后立即成为我们的董事会成员。Ben Zvi博士目前是Bank Leumi的董事会成员和审计、风险管理、技术和战略委员会成员，以及VBL Therapeutics的董事会成员和审计委员会成员。从2004年到2014年，Ben Zvi博士担任梯瓦制药工业有限公司（Teva Pharmaceuticals Industries Ltd.）的多个管理职位，包括财务Vice President和战略Vice President。从2000年到2004年，Ben Zvi博士是以色列国防军总参谋长的财务顾问和国防部预算司司长。Ben Zvi博士拥有以色列特拉维夫大学（Tel-Aviv University）经济学博士学位，并参加了哈佛商学院高级管理课程AMP。
- Shmuel Ben Zvi became a member of Sol-Gel Technologies Ltd. board of directors immediately following pricing of Sol-Gel Technologies Ltd. initial public offering. Dr. Ben Zvi is currently a board ember and member of the risk management, technology, investment and strategy committees at Bank Leumi, and a board member and member of the audit committee and compensation committee of VBL Therapeutics. From 2004 to 2014 Dr. Ben Zvi held various managerial positions at Teva Pharmaceuticals Industries Ltd., including Vice President of Finance and Vice President of Strategy. From 2000 to 2004 Dr. Ben Zvi was the financial advisor to the Chief of General Staff of the Israel Defense Forces and head of the Defense Ministry budget department. Dr. Ben Zvi holds a Ph.D. in economics from Tel-Aviv University, Israel and participated in the Harvard Business School Advanced Management Program AMP.
- Dror Bashan
-
Dror Bashan曾担任Protalix Biotherapeutics, Inc.的董事。自2019年6月起担任Protalix Biotherapeutics, Inc.的总裁兼首席执行官，并担任董事。他在制药行业拥有超过20年的经验，职位包括业务开发、营销、销售和财务，这使他拥有跨区域和跨学科的经验，并对全球制药和健康行业有深刻的了解。从1998年到2018年，他担任Teva Pharmaceutical Industries Ltd（“Teva”）的多个高级职位。（纽约证券交易所：TEVA；家常便饭：TEVA）。最近，他担任Teva全球业务发展高级副总裁，并参与战略联盟、跨公司战略项目和资产收购和剥离。他持有Tel Aviv大学的经济和商业管理学士学位，以及Tel Aviv大学的工商管理硕士学位。
Dror Bashan,has served as Protalix Biotherapeutics, Inc. President and Chief Executive Officer and as Protalix Biotherapeutics, Inc. director since June 2019. From 1998 through 2018, he served in a number of senior positions at Teva Pharmaceutical Industries Ltd ("Teva"). (NYSE:TEVA; TASE:TEVA). Most recently, he served as Teva's Senior Vice President, Global Business Development, and was involved in strategic alliances, cross-company strategic projects and the acquisition and divestiture of assets. Mr. Bashan holds a BA in Economics and Business Management from the Tel Aviv University and an MBA from the Tel Aviv University. - Dror Bashan曾担任Protalix Biotherapeutics, Inc.的董事。自2019年6月起担任Protalix Biotherapeutics, Inc.的总裁兼首席执行官，并担任董事。他在制药行业拥有超过20年的经验，职位包括业务开发、营销、销售和财务，这使他拥有跨区域和跨学科的经验，并对全球制药和健康行业有深刻的了解。从1998年到2018年，他担任Teva Pharmaceutical Industries Ltd（“Teva”）的多个高级职位。（纽约证券交易所：TEVA；家常便饭：TEVA）。最近，他担任Teva全球业务发展高级副总裁，并参与战略联盟、跨公司战略项目和资产收购和剥离。他持有Tel Aviv大学的经济和商业管理学士学位，以及Tel Aviv大学的工商管理硕士学位。
- Dror Bashan,has served as Protalix Biotherapeutics, Inc. President and Chief Executive Officer and as Protalix Biotherapeutics, Inc. director since June 2019. From 1998 through 2018, he served in a number of senior positions at Teva Pharmaceutical Industries Ltd ("Teva"). (NYSE:TEVA; TASE:TEVA). Most recently, he served as Teva's Senior Vice President, Global Business Development, and was involved in strategic alliances, cross-company strategic projects and the acquisition and divestiture of assets. Mr. Bashan holds a BA in Economics and Business Management from the Tel Aviv University and an MBA from the Tel Aviv University.
- Eliot Richard Forster
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Christian Elze
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Pol F. Boudes
-
Pol F. Boudes，于2020年3月2日成为公司的首席医疗官。在加入公司之前，Boudes博士在2014年3月至2019年10月期间担任CymaBay Therapeutics的首席医疗官，在那里他研究了CymaBay的专有NASH化合物，并在发明和启动罕见肝病项目方面发挥了重要作用。在加入CymaBay之前，Boudes博士曾担任爱美医疗的首席医疗官，该公司专注于罕见的溶酶体贮积症。根据这一经验，Boudes博士成为Protalix BioTherapeutics的董事会成员，该公司开发的植物细胞表达重组蛋白具有改进的治疗特性，特别是用于溶酶体疾病。在担任首席医疗官之前，Boudes博士曾在拜耳医药保健、惠氏研究、Hoffman-La Roche和Pasteur Merieux担任临床开发职责增加的职位。
Pol F. Boudes,became the Company's Chief Medical Officer on March 2, 2020. Prior to joining the Company, Dr. Boudes served as the Chief Medical Officer of CymaBay Therapeutics from March 2014 through October 2019, where he worked on CymaBay's proprietary NASH compound and was instrumental in inventing and launching programs in rare liver diseases. Prior to his time at CymaBay, Dr. Boudes served as the Chief Medical Officer of Amicus Therapeutics, a company focusing on rare lysosomal storage disorders. Following this experience, Dr. Boudes became a Board member of Protalix BioTherapeutics, a company developing plant cell expressed recombinant proteins with improved therapeutic profiles, notably for lysosomal disorders. Before his time working as a Chief Medical Officer, Dr. Boudes held positions of increased responsibilities in clinical development at Bayer HealthCare Pharmaceuticals, Wyeth Research, Hoffman-La Roche and Pasteur Merieux. - Pol F. Boudes，于2020年3月2日成为公司的首席医疗官。在加入公司之前，Boudes博士在2014年3月至2019年10月期间担任CymaBay Therapeutics的首席医疗官，在那里他研究了CymaBay的专有NASH化合物，并在发明和启动罕见肝病项目方面发挥了重要作用。在加入CymaBay之前，Boudes博士曾担任爱美医疗的首席医疗官，该公司专注于罕见的溶酶体贮积症。根据这一经验，Boudes博士成为Protalix BioTherapeutics的董事会成员，该公司开发的植物细胞表达重组蛋白具有改进的治疗特性，特别是用于溶酶体疾病。在担任首席医疗官之前，Boudes博士曾在拜耳医药保健、惠氏研究、Hoffman-La Roche和Pasteur Merieux担任临床开发职责增加的职位。
- Pol F. Boudes,became the Company's Chief Medical Officer on March 2, 2020. Prior to joining the Company, Dr. Boudes served as the Chief Medical Officer of CymaBay Therapeutics from March 2014 through October 2019, where he worked on CymaBay's proprietary NASH compound and was instrumental in inventing and launching programs in rare liver diseases. Prior to his time at CymaBay, Dr. Boudes served as the Chief Medical Officer of Amicus Therapeutics, a company focusing on rare lysosomal storage disorders. Following this experience, Dr. Boudes became a Board member of Protalix BioTherapeutics, a company developing plant cell expressed recombinant proteins with improved therapeutic profiles, notably for lysosomal disorders. Before his time working as a Chief Medical Officer, Dr. Boudes held positions of increased responsibilities in clinical development at Bayer HealthCare Pharmaceuticals, Wyeth Research, Hoffman-La Roche and Pasteur Merieux.
- Amos Bar Shalev
-
Amos Bar Shalev，自2008年7月起担任PROTALIX生物疗法，公司董事。此前，Bar Shalev先生于2005年至2008年1月担任Protalix Ltd.的董事，并于2006年至2008年1月担任PROTALIX生物疗法，Inc.的董事。目前，Bar Shalev先生在以下以色列私营公司的董事会任职：Aposense Ltd.和Sirvir Ltd.。2004年至2012年，Bar Shalev先生担任Technorov Holdings（1993）Ltd.的董事并管理其投资组合。从1997年到2004年，他担任TDA Capital Partners的董事总经理，该公司是TGF（Templeton Tadiran）基金的管理公司。2004年至2007年，他担任Win Buyer Ltd.总裁。他曾在多家以色列上市和私营公司的董事会任职，其中包括Steam CC Ltd.、Velox Ltd.、NESS Ltd.（被BioNess Inc.收购）、Idanit（被Scitex Corporation Ltd.收购）、Objet Geometrix（与Stratasys设备（NASDAQ：SSYS）合并）、Verisity、Scitex Vision（被惠普企业收购）、Golden Wings Investment Company Ltd.、以色列空军退伍军人商业俱乐部的风险投资基金，Win Buyer Ltd.和Sun Light Ltd.。他于1978年在以色列理工学院获得电气工程学士学位，并于1981年在特拉维夫大学获得工商管理硕士学位。他拥有以色列空军授予的技术成就最高奖项。
Amos Bar Shalev,has served as Protalix Biotherapeutics, Inc. director since July 2008. Previously, Mr. Bar Shalev served as a director of Protalix Ltd. from 2005 through January 2008, and as Protalix Biotherapeutics, Inc. director from 2006 through January 2008.Currently, Mr. Bar Shalev serves on the Board of Directors of the following privately-held Israeli companies: Aposense Ltd. and Sirvir Ltd. From 2004 through 2012, Mr. Bar Shalev served as a director of Technorov Holdings (1993) Ltd. and managed its portfolio. From 1997 through 2004, he was a Managing Director of TDA Capital Partners, a management company of the TGF (Templeton Tadiran) Fund. From 2004 through 2007, he was the President of Win Buyer Ltd. He has served on the Board of Directors of a number of Israeli publicly traded and privately-held Israeli companies including, among others, Steam CC Ltd., Velox Ltd., NESS Ltd. (acquired by BioNess Inc.), Idanit (acquired by Scitex Corporation Ltd.), Objet Geometrix (merged with Stratasys, Inc. (NASDAQ:SSYS)), Verisity, Scitex Vision (acquired by Hewlett Packard), Golden Wings Investment Company Ltd., the venture capital fund of the Israeli Air Force Veterans Business Club, Win Buyer Ltd. and Sun Light Ltd. He received his B.Sc. in Electrical Engineering from the Technion, Israel in 1978 and M.B.A. from the Tel Aviv University in 1981. He holds the highest award from the Israeli Air Force for technological achievements. - Amos Bar Shalev，自2008年7月起担任PROTALIX生物疗法，公司董事。此前，Bar Shalev先生于2005年至2008年1月担任Protalix Ltd.的董事，并于2006年至2008年1月担任PROTALIX生物疗法，Inc.的董事。目前，Bar Shalev先生在以下以色列私营公司的董事会任职：Aposense Ltd.和Sirvir Ltd.。2004年至2012年，Bar Shalev先生担任Technorov Holdings（1993）Ltd.的董事并管理其投资组合。从1997年到2004年，他担任TDA Capital Partners的董事总经理，该公司是TGF（Templeton Tadiran）基金的管理公司。2004年至2007年，他担任Win Buyer Ltd.总裁。他曾在多家以色列上市和私营公司的董事会任职，其中包括Steam CC Ltd.、Velox Ltd.、NESS Ltd.（被BioNess Inc.收购）、Idanit（被Scitex Corporation Ltd.收购）、Objet Geometrix（与Stratasys设备（NASDAQ：SSYS）合并）、Verisity、Scitex Vision（被惠普企业收购）、Golden Wings Investment Company Ltd.、以色列空军退伍军人商业俱乐部的风险投资基金，Win Buyer Ltd.和Sun Light Ltd.。他于1978年在以色列理工学院获得电气工程学士学位，并于1981年在特拉维夫大学获得工商管理硕士学位。他拥有以色列空军授予的技术成就最高奖项。
- Amos Bar Shalev,has served as Protalix Biotherapeutics, Inc. director since July 2008. Previously, Mr. Bar Shalev served as a director of Protalix Ltd. from 2005 through January 2008, and as Protalix Biotherapeutics, Inc. director from 2006 through January 2008.Currently, Mr. Bar Shalev serves on the Board of Directors of the following privately-held Israeli companies: Aposense Ltd. and Sirvir Ltd. From 2004 through 2012, Mr. Bar Shalev served as a director of Technorov Holdings (1993) Ltd. and managed its portfolio. From 1997 through 2004, he was a Managing Director of TDA Capital Partners, a management company of the TGF (Templeton Tadiran) Fund. From 2004 through 2007, he was the President of Win Buyer Ltd. He has served on the Board of Directors of a number of Israeli publicly traded and privately-held Israeli companies including, among others, Steam CC Ltd., Velox Ltd., NESS Ltd. (acquired by BioNess Inc.), Idanit (acquired by Scitex Corporation Ltd.), Objet Geometrix (merged with Stratasys, Inc. (NASDAQ:SSYS)), Verisity, Scitex Vision (acquired by Hewlett Packard), Golden Wings Investment Company Ltd., the venture capital fund of the Israeli Air Force Veterans Business Club, Win Buyer Ltd. and Sun Light Ltd. He received his B.Sc. in Electrical Engineering from the Technion, Israel in 1978 and M.B.A. from the Tel Aviv University in 1981. He holds the highest award from the Israeli Air Force for technological achievements.
- Aharon Schwartz
-
Aharon Schwartz，自2014年11月起担任Protalix Biotherapeutics, Inc.董事。他于2011年从Teva退休，从1975年到2011年担任多个职位，最近的职位是副总裁，2008年担任Teva Innovative Ventures的负责人。他目前是BiolineRx Ltd. （NASDAQ：BLRX, TASE：BLRX）的董事会主席和Barcode Ltd.的董事会成员。他还担任Oncohost Ltd.的顾问委员会主席，并担任独立顾问。从2015年5月到2020年3月，他担任Foamix Pharmaceuticals Ltd.（Nasdaq：FOMX）的董事会成员，该公司被Menlo Therapeutics Inc.（Nasdaq：MNLO）收购。从2013年1月到2017年11月，他担任Alcobra Ltd.（现称为Arcturus Therapeutics Ltd.）的董事会成员。他于1978年获得Weizmann科学研究所的有机化学博士学位，Technion的有机化学硕士学位，以及耶路撒冷希伯来大学的化学和物理学士学位。他于2014年获得耶路撒冷希伯来大学科学历史和哲学的第二个博士学位。
Aharon Schwartz,has served as Protalix Biotherapeutics, Inc. director since November 2014. He retired from Teva in 2011 where he served in a number of positions from 1975 through 2011, the most recent being Vice President, Head of Teva Innovative Ventures from 2008. Dr. Schwartz is currently chairman of the Board of Directors of BiolineRx Ltd. (NASDAQ:BLRX, TASE:BLRX) and a member of the Board of Directors of Barcode Ltd. He also serves as the Head of the Advisory Board of Oncohost Ltd. and works as an independent consultant. From May 2015 through March 2020, he served as a member of the Board of Directors of Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX), which was acquired by Menlo Therapeutics Inc. (Nasdaq: MNLO), and from January 2013 through November 2017, he served as a member of the Board of Directors of Alcobra Ltd., which is now called Arcturus Therapeutics Ltd. Dr. Schwartz received his Ph.D. in organic chemistry in 1978 from the Weizmann Institute of Science, his M.Sc. in organic chemistry from the Technion and a B.Sc. in chemistry and physics from the Hebrew University of Jerusalem. Dr. Schwartz received a second Ph.D. in 2014 from the Hebrew University of Jerusalem in the history and philosophy of science. - Aharon Schwartz，自2014年11月起担任Protalix Biotherapeutics, Inc.董事。他于2011年从Teva退休，从1975年到2011年担任多个职位，最近的职位是副总裁，2008年担任Teva Innovative Ventures的负责人。他目前是BiolineRx Ltd. （NASDAQ：BLRX, TASE：BLRX）的董事会主席和Barcode Ltd.的董事会成员。他还担任Oncohost Ltd.的顾问委员会主席，并担任独立顾问。从2015年5月到2020年3月，他担任Foamix Pharmaceuticals Ltd.（Nasdaq：FOMX）的董事会成员，该公司被Menlo Therapeutics Inc.（Nasdaq：MNLO）收购。从2013年1月到2017年11月，他担任Alcobra Ltd.（现称为Arcturus Therapeutics Ltd.）的董事会成员。他于1978年获得Weizmann科学研究所的有机化学博士学位，Technion的有机化学硕士学位，以及耶路撒冷希伯来大学的化学和物理学士学位。他于2014年获得耶路撒冷希伯来大学科学历史和哲学的第二个博士学位。
- Aharon Schwartz,has served as Protalix Biotherapeutics, Inc. director since November 2014. He retired from Teva in 2011 where he served in a number of positions from 1975 through 2011, the most recent being Vice President, Head of Teva Innovative Ventures from 2008. Dr. Schwartz is currently chairman of the Board of Directors of BiolineRx Ltd. (NASDAQ:BLRX, TASE:BLRX) and a member of the Board of Directors of Barcode Ltd. He also serves as the Head of the Advisory Board of Oncohost Ltd. and works as an independent consultant. From May 2015 through March 2020, he served as a member of the Board of Directors of Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX), which was acquired by Menlo Therapeutics Inc. (Nasdaq: MNLO), and from January 2013 through November 2017, he served as a member of the Board of Directors of Alcobra Ltd., which is now called Arcturus Therapeutics Ltd. Dr. Schwartz received his Ph.D. in organic chemistry in 1978 from the Weizmann Institute of Science, his M.Sc. in organic chemistry from the Technion and a B.Sc. in chemistry and physics from the Hebrew University of Jerusalem. Dr. Schwartz received a second Ph.D. in 2014 from the Hebrew University of Jerusalem in the history and philosophy of science.
- Gwen A. Melincoff
-
Gwen A. Melincoff于2020年1月加入Protalix Biotherapeutics, Inc.董事。她是一位业务发展和风险投资专业人士，在生物技术和制药行业拥有超过25年的交易撮合和管理经验。她的经验涵盖上市和私人公司董事会、风险融资、业务发展、许可、合并和收购、研究运营、营销、产品管理和项目管理。她目前担任Gain Therapeutics, Inc. （NASDAQ：GANX）， Collegium Pharmaceutical, Inc. （NASDAQ：COLL）和Soleno Therapeutics, Inc. （NASDAQ：SOLN）的董事会成员。她还在一些制药公司担任顾问职务。从2017年4月到2020年6月她在Photocure ASA的董事会，从2017年1月到2019年1月她的董事会Kamada有限公司（NASDAQ：KMDA, TASE：KMDA），从2014年6月到2016年11月，她曾在董事会Tobira疗法Inc 。（Allergan plc公司收购）。从2014年8月到2016年9月，她担任BTG International Inc.的业务发展副总裁。在此之前，她是Shire Plc公司发展高级副总裁。此外，她领导Shire战略投资集团，这是Shire Plc的风险投资部门。她曾担任Adolor Corporation的业务发展副总裁，并在Eastman Kodak的一些医疗保健公司担任执行职务超过10年。她持有The George Washington University的生物学学士学位和Pennsylvania State University的管理和卫生保健管理硕士学位。Melincoff女士还获得了Certified Licensing Professional （CLP）的指定。她于2012年和2013年被Fierce Biotech公司提名为“2013年生物技术领域的顶级女性”，并获得了Corporate Venture Capital的Powerlist 100。
Gwen A. Melincoff,joined Protalix Biotherapeutics, Inc. Board of Directors in January 2020. Her experience has spanned public and private company boards, venture financing, business development, licensing, mergers and acquisitions, research operations, marketing, product management and project management. Ms. Melincoff currently serves on the Board of Directors of Gain Therapeutics, Inc. (NASDAQ:GANX), Soleno Therapeutics, Inc. (NASDAQ:SOLN) and Collegium Pharmaceutical, Inc. (NASDAQ:COLL). She also serves in an advisory capacity at a number of pharmaceutical companies. From April 2017 through June 2020, she served on the Board of Directors of Photocure ASA, from January 2017 through January 2019, she served on the Board of Directors of Kamada Ltd. (NASDAQ:KMDA, TASE:KMDA), and from June 2014 through November 2016, she served on the Board of Directors of Tobira Therapeutics Inc. (acquired by Allergan plc). From August 2014 through September 2016, Ms. Melincoff served as Vice President of Business Development at BTG International Inc. Prior to that, she was Senior Vice President of Corporate Development at Shire Plc. Additionally, she led the Shire Strategic Investment Group, the venture capital arm of Shire Plc. Ms. Melincoff was Vice President of Business Development at Adolor Corporation and held executive positions at Eastman Kodak for over ten years in a number of their health care companies. She holds a B.S. in Biology from The George Washington University and an M.S. in Management and Health Care Administration from Pennsylvania State University. Ms. Melincoff has also attained the designation of Certified Licensing Professional (CLP). Ms. Melincoff was named to the "Top Women in Biotech 2013" by Fierce Biotech and to the Powerlist 100 of Corporate Venture Capital in 2012 and 2013. - Gwen A. Melincoff于2020年1月加入Protalix Biotherapeutics, Inc.董事。她是一位业务发展和风险投资专业人士，在生物技术和制药行业拥有超过25年的交易撮合和管理经验。她的经验涵盖上市和私人公司董事会、风险融资、业务发展、许可、合并和收购、研究运营、营销、产品管理和项目管理。她目前担任Gain Therapeutics, Inc. （NASDAQ：GANX）， Collegium Pharmaceutical, Inc. （NASDAQ：COLL）和Soleno Therapeutics, Inc. （NASDAQ：SOLN）的董事会成员。她还在一些制药公司担任顾问职务。从2017年4月到2020年6月她在Photocure ASA的董事会，从2017年1月到2019年1月她的董事会Kamada有限公司（NASDAQ：KMDA, TASE：KMDA），从2014年6月到2016年11月，她曾在董事会Tobira疗法Inc 。（Allergan plc公司收购）。从2014年8月到2016年9月，她担任BTG International Inc.的业务发展副总裁。在此之前，她是Shire Plc公司发展高级副总裁。此外，她领导Shire战略投资集团，这是Shire Plc的风险投资部门。她曾担任Adolor Corporation的业务发展副总裁，并在Eastman Kodak的一些医疗保健公司担任执行职务超过10年。她持有The George Washington University的生物学学士学位和Pennsylvania State University的管理和卫生保健管理硕士学位。Melincoff女士还获得了Certified Licensing Professional （CLP）的指定。她于2012年和2013年被Fierce Biotech公司提名为“2013年生物技术领域的顶级女性”，并获得了Corporate Venture Capital的Powerlist 100。
- Gwen A. Melincoff,joined Protalix Biotherapeutics, Inc. Board of Directors in January 2020. Her experience has spanned public and private company boards, venture financing, business development, licensing, mergers and acquisitions, research operations, marketing, product management and project management. Ms. Melincoff currently serves on the Board of Directors of Gain Therapeutics, Inc. (NASDAQ:GANX), Soleno Therapeutics, Inc. (NASDAQ:SOLN) and Collegium Pharmaceutical, Inc. (NASDAQ:COLL). She also serves in an advisory capacity at a number of pharmaceutical companies. From April 2017 through June 2020, she served on the Board of Directors of Photocure ASA, from January 2017 through January 2019, she served on the Board of Directors of Kamada Ltd. (NASDAQ:KMDA, TASE:KMDA), and from June 2014 through November 2016, she served on the Board of Directors of Tobira Therapeutics Inc. (acquired by Allergan plc). From August 2014 through September 2016, Ms. Melincoff served as Vice President of Business Development at BTG International Inc. Prior to that, she was Senior Vice President of Corporate Development at Shire Plc. Additionally, she led the Shire Strategic Investment Group, the venture capital arm of Shire Plc. Ms. Melincoff was Vice President of Business Development at Adolor Corporation and held executive positions at Eastman Kodak for over ten years in a number of their health care companies. She holds a B.S. in Biology from The George Washington University and an M.S. in Management and Health Care Administration from Pennsylvania State University. Ms. Melincoff has also attained the designation of Certified Licensing Professional (CLP). Ms. Melincoff was named to the "Top Women in Biotech 2013" by Fierce Biotech and to the Powerlist 100 of Corporate Venture Capital in 2012 and 2013.
高管简历
中英对照 | 中文 | 英文- Gilad Mamlok
Gilad Mamlok，最近担任远程医疗保健领域的私营公司TytoCare Ltd.的首席财务官（2024年7月至2025年7月）。在任职TytoCare之前，从2017年2月到2024年7月，Mamlok先生担任Sol-gel Technologies Ltd.的首席财务官。在担任这一职务时，他负责首次公开发行股票和其他资本市场交易，以及许可内交易和许可外交易。在加入Sol-Gel之前，他曾在其他医疗设备公司任职，包括2014年被Covidien plc收购的Given Imaging。Mamlok先生以优异成绩获得了特拉维夫大学的经济学学士学位和商业/管理经济学硕士学位。
Gilad Mamlok,most recently served as the Chief Financial Officer of TytoCare Ltd., a privately-held company in the remote healthcare space (from July 2024 through July 2025). Prior to his role at TytoCare, from February 2017 through July 2024, Mr. Mamlok served as the Chief Financial Officer of Sol-Gel Technologies Ltd. In this role, he was responsible for an initial public offering and other capital markets transactions, as well as in-licensing and out-licensing transactions. Prior to his role at Sol-Gel, he served in other medical device companies, including Given Imaging which was acquired by Covidien plc in 2014. Mr. Mamlok holds a BA in Economics, magna cum laude, and a Master's degree in Business/Managerial Economics, both from the Tel Aviv University.- Gilad Mamlok，最近担任远程医疗保健领域的私营公司TytoCare Ltd.的首席财务官（2024年7月至2025年7月）。在任职TytoCare之前，从2017年2月到2024年7月，Mamlok先生担任Sol-gel Technologies Ltd.的首席财务官。在担任这一职务时，他负责首次公开发行股票和其他资本市场交易，以及许可内交易和许可外交易。在加入Sol-Gel之前，他曾在其他医疗设备公司任职，包括2014年被Covidien plc收购的Given Imaging。Mamlok先生以优异成绩获得了特拉维夫大学的经济学学士学位和商业/管理经济学硕士学位。
- Gilad Mamlok,most recently served as the Chief Financial Officer of TytoCare Ltd., a privately-held company in the remote healthcare space (from July 2024 through July 2025). Prior to his role at TytoCare, from February 2017 through July 2024, Mr. Mamlok served as the Chief Financial Officer of Sol-Gel Technologies Ltd. In this role, he was responsible for an initial public offering and other capital markets transactions, as well as in-licensing and out-licensing transactions. Prior to his role at Sol-Gel, he served in other medical device companies, including Given Imaging which was acquired by Covidien plc in 2014. Mr. Mamlok holds a BA in Economics, magna cum laude, and a Master's degree in Business/Managerial Economics, both from the Tel Aviv University.
- Dror Bashan
Dror Bashan曾担任Protalix Biotherapeutics, Inc.的董事。自2019年6月起担任Protalix Biotherapeutics, Inc.的总裁兼首席执行官，并担任董事。他在制药行业拥有超过20年的经验，职位包括业务开发、营销、销售和财务，这使他拥有跨区域和跨学科的经验，并对全球制药和健康行业有深刻的了解。从1998年到2018年，他担任Teva Pharmaceutical Industries Ltd（“Teva”）的多个高级职位。（纽约证券交易所：TEVA；家常便饭：TEVA）。最近，他担任Teva全球业务发展高级副总裁，并参与战略联盟、跨公司战略项目和资产收购和剥离。他持有Tel Aviv大学的经济和商业管理学士学位，以及Tel Aviv大学的工商管理硕士学位。
Dror Bashan,has served as Protalix Biotherapeutics, Inc. President and Chief Executive Officer and as Protalix Biotherapeutics, Inc. director since June 2019. From 1998 through 2018, he served in a number of senior positions at Teva Pharmaceutical Industries Ltd ("Teva"). (NYSE:TEVA; TASE:TEVA). Most recently, he served as Teva's Senior Vice President, Global Business Development, and was involved in strategic alliances, cross-company strategic projects and the acquisition and divestiture of assets. Mr. Bashan holds a BA in Economics and Business Management from the Tel Aviv University and an MBA from the Tel Aviv University.- Dror Bashan曾担任Protalix Biotherapeutics, Inc.的董事。自2019年6月起担任Protalix Biotherapeutics, Inc.的总裁兼首席执行官，并担任董事。他在制药行业拥有超过20年的经验，职位包括业务开发、营销、销售和财务，这使他拥有跨区域和跨学科的经验，并对全球制药和健康行业有深刻的了解。从1998年到2018年，他担任Teva Pharmaceutical Industries Ltd（“Teva”）的多个高级职位。（纽约证券交易所：TEVA；家常便饭：TEVA）。最近，他担任Teva全球业务发展高级副总裁，并参与战略联盟、跨公司战略项目和资产收购和剥离。他持有Tel Aviv大学的经济和商业管理学士学位，以及Tel Aviv大学的工商管理硕士学位。
- Dror Bashan,has served as Protalix Biotherapeutics, Inc. President and Chief Executive Officer and as Protalix Biotherapeutics, Inc. director since June 2019. From 1998 through 2018, he served in a number of senior positions at Teva Pharmaceutical Industries Ltd ("Teva"). (NYSE:TEVA; TASE:TEVA). Most recently, he served as Teva's Senior Vice President, Global Business Development, and was involved in strategic alliances, cross-company strategic projects and the acquisition and divestiture of assets. Mr. Bashan holds a BA in Economics and Business Management from the Tel Aviv University and an MBA from the Tel Aviv University.
- Yaron Naos
Yaron Naos于2004年加入Protalix，最初担任运营高级总监，后来担任生产副总裁，并于2018年成为运营高级副总裁。Naos先生在药物开发领域拥有丰富的实践经验和知识。加入Protalix之前，他担任了长达十年的研发产品经理在Dexxon药业有限公司，以色列最大的制药公司之一，在那里他负责技术转让从研发到生产，负责研发活动导致了许多产品的商业化。之后，Naos先生担任Medibrands Pharmaceutical Company的工厂经理，以及Mediline的物流经理（4年），在那里他负责所有的运营活动，从采购到分销。Naos先生持有the Technion-Israel Technology Institute的食品工程和生物技术学士学位，以及Haifa University的工商管理硕士学位。
Yaron Naos,joined Protalix in 2004, originally as a Senior Director for Operations and later as Vice President for Production, and became Protalix Biotherapeutics, Inc. Senior Vice President, Operations in 2018.Prior to joining Protalix, he served for a decade as R&D Product Manager at Dexxon Pharmaceutical Co., one of Israel's largest pharmaceutical companies, where he was responsible for technology transfer from R&D to production, and in charge of R&D activities that led to the commercialization of many products. Later, Mr. Naos was plant manager of Medibrands Pharmaceutical Company, as well as logistics manager of Mediline for period of four years, where he was responsible for all operational activities, from procurement to distribution. Mr. Naos holds a B.Sc. in Food Engineering and Biotechnology from the Technion-Israel Technology Institute and an MBA from Haifa University.- Yaron Naos于2004年加入Protalix，最初担任运营高级总监，后来担任生产副总裁，并于2018年成为运营高级副总裁。Naos先生在药物开发领域拥有丰富的实践经验和知识。加入Protalix之前，他担任了长达十年的研发产品经理在Dexxon药业有限公司，以色列最大的制药公司之一，在那里他负责技术转让从研发到生产，负责研发活动导致了许多产品的商业化。之后，Naos先生担任Medibrands Pharmaceutical Company的工厂经理，以及Mediline的物流经理（4年），在那里他负责所有的运营活动，从采购到分销。Naos先生持有the Technion-Israel Technology Institute的食品工程和生物技术学士学位，以及Haifa University的工商管理硕士学位。
- Yaron Naos,joined Protalix in 2004, originally as a Senior Director for Operations and later as Vice President for Production, and became Protalix Biotherapeutics, Inc. Senior Vice President, Operations in 2018.Prior to joining Protalix, he served for a decade as R&D Product Manager at Dexxon Pharmaceutical Co., one of Israel's largest pharmaceutical companies, where he was responsible for technology transfer from R&D to production, and in charge of R&D activities that led to the commercialization of many products. Later, Mr. Naos was plant manager of Medibrands Pharmaceutical Company, as well as logistics manager of Mediline for period of four years, where he was responsible for all operational activities, from procurement to distribution. Mr. Naos holds a B.Sc. in Food Engineering and Biotechnology from the Technion-Israel Technology Institute and an MBA from Haifa University.
- Gilad Mamlok
Gilad Mamlok，最近担任远程医疗保健领域的私营公司TytoCare Ltd.的首席财务官（2024年7月至2025年7月）。在任职TytoCare之前，从2017年2月到2024年7月，Mamlok先生担任Sol-gel Technologies Ltd.的首席财务官。在担任这一职务时，他负责首次公开发行股票和其他资本市场交易，以及许可内交易和许可外交易。在加入Sol-Gel之前，他曾在其他医疗设备公司任职，包括2014年被Covidien plc收购的Given Imaging。Mamlok先生以优异成绩获得了特拉维夫大学的经济学学士学位和商业/管理经济学硕士学位。
Gilad Mamlok,most recently served as the Chief Financial Officer of TytoCare Ltd., a privately-held company in the remote healthcare space (from July 2024 through July 2025). Prior to his role at TytoCare, from February 2017 through July 2024, Mr. Mamlok served as the Chief Financial Officer of Sol-Gel Technologies Ltd. In this role, he was responsible for an initial public offering and other capital markets transactions, as well as in-licensing and out-licensing transactions. Prior to his role at Sol-Gel, he served in other medical device companies, including Given Imaging which was acquired by Covidien plc in 2014. Mr. Mamlok holds a BA in Economics, magna cum laude, and a Master's degree in Business/Managerial Economics, both from the Tel Aviv University.- Gilad Mamlok，最近担任远程医疗保健领域的私营公司TytoCare Ltd.的首席财务官（2024年7月至2025年7月）。在任职TytoCare之前，从2017年2月到2024年7月，Mamlok先生担任Sol-gel Technologies Ltd.的首席财务官。在担任这一职务时，他负责首次公开发行股票和其他资本市场交易，以及许可内交易和许可外交易。在加入Sol-Gel之前，他曾在其他医疗设备公司任职，包括2014年被Covidien plc收购的Given Imaging。Mamlok先生以优异成绩获得了特拉维夫大学的经济学学士学位和商业/管理经济学硕士学位。
- Gilad Mamlok,most recently served as the Chief Financial Officer of TytoCare Ltd., a privately-held company in the remote healthcare space (from July 2024 through July 2025). Prior to his role at TytoCare, from February 2017 through July 2024, Mr. Mamlok served as the Chief Financial Officer of Sol-Gel Technologies Ltd. In this role, he was responsible for an initial public offering and other capital markets transactions, as well as in-licensing and out-licensing transactions. Prior to his role at Sol-Gel, he served in other medical device companies, including Given Imaging which was acquired by Covidien plc in 2014. Mr. Mamlok holds a BA in Economics, magna cum laude, and a Master's degree in Business/Managerial Economics, both from the Tel Aviv University.